Increased frequency of hematopoietic malignancies in relatives of patients with lymphoid neoplasms: a French case-control study. by Villeneuve, Sara et al.
Increased frequency of hematopoietic malignancies in
relatives of patients with lymphoid neoplasms: a French
case-control study.
Sara Villeneuve, Laurent Orsi, Alain Monnereau, Christian Berthou, Pierre
Fenaux, Gerald Marit, Pierre Soubeyran, Franc¸oise Huguet, Noe¨l Milpied,
Michel Leporrier, et al.
To cite this version:
Sara Villeneuve, Laurent Orsi, Alain Monnereau, Christian Berthou, Pierre Fenaux, et al..
Increased frequency of hematopoietic malignancies in relatives of patients with lymphoid neo-
plasms: a French case-control study.. International Journal of Cancer, Wiley, 2009, 124 (5),
pp.1188-95. <10.1002/ijc.24026>. <inserm-00354410>
HAL Id: inserm-00354410
http://www.hal.inserm.fr/inserm-00354410
Submitted on 4 Sep 2009
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
INCREASED FREQUENCY OF HEMATOPOIETIC MALIGNANCIES IN RELATIVES OF 
PATIENTS WITH LYMPHOID NEOPLASMS: A FRENCH CASE-CONTROL STUDY 
S Villeneuve1,2, L Orsi1,2, A Monnereau1,2,3,4, C Berthou5, P Fenaux6, G Marit7,8, P Soubeyran3,8, F 
Huguet9, N Milpied7,8, M Leporrier10, D Hemon1,2, X Troussard11,12, and J Clavel1,2 
Short title: Familial aggregation in hematopoietic malignancy 
Correspondance to: 
Jacqueline Clavel MD PhD 
Inserm U754 
16, av. Paul Vaillant-Couturier 
F-94807 VILLEJUIF Cedex 
jacqueline.clavel@inserm.fr 
fax: 01 45 59 51 51 
 
Key-words: 
Epidemiology, lymphoid neoplasm, family, aetiology 
 
1
 INSERM, U754, IFR69, Villejuif, France 
2
 Univ Paris-Sud, UMR-S754, IFR69, Villejuif, France 
3
 Bergonié Institute, Comprehensive cancer center, Bordeaux, France 
4
 Hematological Malignancies Registry of Gironde, Bordeaux, France 
5 Morvan Hospital, Brest, France 
6 Hôp Avicenne AP-HP, Université Paris 13, Bobigny, France 
7 CHU de Bordeaux, Pessac, France 
8 Université Bordeaux 2, France 
9 CHU Purpan, Toulouse, France 
10
 CHU Caen-Clemenceau Hospital, Caen France 
11 CHU Caen-Côte de Nacre Hospital, Caen, France 
12
 Haematological Malignancies Registry of Basse Normandie, Caen, France 
 
 2 
Abstract 
Lymphoid neoplasms (LN), including non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL), 
lymphoproliferative syndrome (LPS) and multiple myeloma (MM), are among the most frequent 
cancers (approximately 17,000 new cases per year in France), after those related to smoking. LN were 
investigated using the data from the ENGELA study. ENGELA is a multicenter hospital-based case-
control study that was carried out in France over the period September 2000 – December2004. In all, 
822 cases (397 NHL, 149 LH, 168 SLP and 108 MM) and 752 controls were included and described 
5481 and 5188 first degree relatives, respectively. A positive association with a familial history of 
hematopoietic cancer was observed for LN (OR = 1.7 [1.0-2.8]) overall and for LPS (OR = 3.2 [1.4-
6.8]). The associations with HL (OR = 10.4 [2.0-53.8]) and NHL (OR = 2.4 [1.0-5.9]) were stronger 
for men. The associations were also stronger when the disease had been diagnosed before the relatives 
were aged 45 years. The results mainly support the involvement of genetic factors and suggest that at 
least some of those factors may be sex-linked. However, the slight overrepresentation of affected 
spouses among the cases might also support the responsibility of environmental factors. 
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INTRODUCTION 
Lymphoid neoplasm (LN), including Hodgkin’s lymphoma (HL), non-Hodgkin’s lymphoma (NHL), 
multiple myeloma (MM) and lymphoproliferative syndromes (LPS) are among the most common 
cancers in France after smoking-related cancers. According to data from French registries, there were 
approximately 17,000 new cases of LN in 2000 and almost 9,000 deaths 1. In the last two decades 
(1978-2000), the yearly incidence rate for NHL has increased by more than 3% (3.8% for men and 
3.5% for women), for reasons that have yet to be elucidated 1. 
A few risk factors for lymphoid neoplasms have been identified. They include congenital and acquired 
immunodeficiencies2-3-4-5, chromosomal instability syndromes 6-7, Epstein-Barr Virus (EBV) infection 
8
-
9
-
10
 for some Burkitt’s 11-10 and Hodgkin’s lymphomas, Helicobacter pylori infection for gastric 
lymphoma 12-13 and some autoimmune disorders for non-Hodgkin lymphoma14-15-16-17. Farming and 
exposure to pesticides 18-19-20 have also been consistently associated with LN. 
Several studies have investigated the relationships between familial hematopoietic cancer aggregation 
and hematopoietic cancer and suggest a two-fold increase in the risk of NHL 21-22-23-24, and HL 25 with 
a history of NHL in first degree relatives. 
This study analyzed the association between LN and familial history of cancer in the first-degree 
relatives of the subjects included in a large case-control study designed to investigate for 
environmental and genetic risk factors for LN. 
MATERIALS AND METHODS 
The ENGELA study is a French multicenter hospital-based case-control study that was conducted in 
the main hospitals of Bordeaux, Brest, Caen, Nantes, Lille and Toulouse from September 2000 to 
December 2004 in order to investigate for environmental, infectious and genetics risk factors for LN. 
The LN types considered in the study were LPS, which included chronic lymphoid leukaemia (CLL) 
and hairy cell leukaemia (HCL), NHL, HL and MM. 
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Cases and controls ascertainment 
The eligible cases were subjects aged between 18 and 75 years old, recently diagnosed with LN, and 
residing in the catchment area of each hospital. The diagnosis of LN was documented by cytology and 
histology, and reviewed by a team of pathologists. All the cases were coded using the WHO 
classification (ICD-O-3). Cases with AIDS or treated with immunosuppressant drugs were not 
eligible. The inclusion of the cases took place within 6 months of diagnosis, except for LPS cases, who 
could be included up to 18 months post-diagnosis, in view of their good prognosis. 
The controls were patients with no prior history of LN, recruited in the same hospital as the cases, 
mainly in orthopaedic and rheumatologic departments. The patients admitted for cancer or a disease 
directly related to occupation, smoking or alcohol consumption were not eligible as controls in order 
to avoid over-representation of some factors of interest. The controls were matched with cases by 
centre, age (± 3 years) and gender. 
Out of the 872 eligible cases, 48 (5.5%) refused to participate. In addition, 2 cases who had been 
adopted were excluded from the analysis. Out of the 853 eligible controls, 100 refused the interview 
(11.7%) and one subject whose interview was incomplete was excluded a posteriori. 
The study sample finally comprised 822 cases of LN, classified using ICD-O-3, and further subdivided 
into four categories: HL (n = 149, ICD-O-3 codes (9650-9655/3, 9659/3, 9661-9665/3, 9667/3)), NHL 
(n = 397 consisting of 172 cases of diffuse large B cell-lymphoma (DLCL) (9679/3, 9680/3), 101 
cases of follicular lymphoma (FL) (9690/3, 9691/3, 9695/3, 9698/3), 21 cases of lymphoplasmacytic 
lymphoma/Waldenstrom macroglobulinemia (9671/3, 9761/3), 17 cases of marginal zone B-cell 
lymphoma of the MALT type (9699/3), 3 cases of splenic marginal zone B-cell lymphoma (9689/3), 
25 cases of T-cell lymphoma (9702/3, 9705/3, 9714/3, 9729/3), 25 cases of mantle-cell lymphoma 
(9673/3), and 33 cases of other lymphoma (9728/3, 9687/3, 9826/3, 9591/3)), MM (n = 108, (9731-
9732/3)) and LPS (n = 168, 132 cases of chronic lymphocytic leukemia (CLL) (9823/3, 9670/3) and 
36 cases of hairy cell leukemia (HCL) (9940/3)) and 752 controls. 
 
Data collection 
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The data were collected in two stages. First, the cases and controls completed a standardized self-
administered questionnaire eliciting information on their socioeconomic characteristics, familial 
medical history and lifetime residential and occupational histories. The patients were asked to describe 
each of their first-degree relatives (gender, year of birth and, if applicable, year of death) and report 
each relative's history of cancer, leukemia or lymphoma, with details of cancer sites and years of 
occurrence. Each relative's age was considered to be that at the time of interview or death. 
Each patient then underwent a face-to-face interview by a trained interviewer using a standardized 
questionnaire addressing personal medical history, lifestyle characteristics (smoking and alcohol, tea 
and coffee consumption), outdoor leisure activities and non-occupational exposure. The self-
administered questionnaire was also checked by the interviewer. 
Blood samples were obtained from the cases and controls after consent form signature and biological 
specimens (constitutional DNA, tumor tissue) were placed on storage. 
The blood samples and interviews were rendered anonymous. 
Statistical analysis 
Analyses were carried out for all LN taken together, for LN types LPS, NHL, HL and MM separately, 
and for the LPS (CLL and HCL) and NHL (DLCL and FL) subtypes. 
The pair-matching used as a basis for the recruitment was broken in order to enable the whole control 
group to be used for the analysis of all LN. For each subgroup, the control group consisted in all 
controls that could be included in one of the age-gender-centre strata covered by the corresponding 
subgroup of cases. 
Unconditional logistic regression was used to estimate the odds ratios (OR) and 95% confidence 
intervals (95% CI). The analyses were systematically adjusted for the stratification variables: age, 
centre and gender. Additional analyses including familial structure and socioeconomic category (blue 
collar, white collar, unemployed) in the models were also conducted. 
The relatives' malignancies were considered overall (any cancer), by large group (solid cancer or 
hematopoietic cancer) and by disease site. The analysis also took into account the type of relative 
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(parent, child, sibling), the age at onset of the earliest cancer in the family, the gender of the relatives 
with cancer, and the total number of relatives with cancer in the family. 
Sensitivity analyses were also conducted to evaluate the robustness of the results. Each centre and 
each category of the controls’ reasons for admission was excluded in turn. Additional analyses 
restricted to the matched samples were also carried out using conditional logistic regression models. 
The SAS software package (version 9, Cary, NC) was used for the analyses. All p values were two-
tailed. 
RESULTS 
Case and control comparability 
The distribution of the 822 cases and 752 controls by the stratification variables, centre, age and 
gender, is shown in Table 1. Significant differences between centre were observed, mainly because the 
Caen hospital had higher LPS recruitment than the others. The use of the whole control group assigned 
more than 2 controls to each case in most strata, except in the youngest categories, in which HL 
predominated. The MM cases differed from the controls with regard to gender since they did not show 
the male predominance observed in other lymphoid neoplasms. The cases of HL were more educated 
and had higher socioeconomic status than the controls (Table 2). The cases and controls described 
5481 (6.5 per subject on average) and 5188 (6.7 per subject on average) first degree relatives, 
respectively, and did not differ in terms of the number of relatives or the relatives' mean age. (Table 1 
and Table 2 here) 
Family history of cancer 
Having at least one relative with a history of cancer was reported by 44.8% of the cases and 42.2% of 
the controls. None of the LN types was associated with a history of cancer in relatives (Table 3). 
However, having had at least 2 relatives with cancer was associated with LPS. 
In contrast, having at least one relative with a history of hematopoietic cancer was reported by 5.8% of 
the cases and 3.5% of the controls. A family history of hematopoietic cancer was significantly 
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associated with LN overall (OR = 1.7 [1.0-2.8]), and with LPS in particular (OR = 3.2 [1.4-6.8]). An 
elevated OR of 2.4 ([0.8-7.1]) was also observed for HL, but was not statistically significant. The 
association with LN and with LN subtypes was rather weak for the younger patients and stronger for 
the age group, 45-60 years. 
The analyses stratified by gender showed that some associations were restricted to men. Among men, 
HL and NHL were significantly related to a familial history of hematopoietic cancer, with OR of 10.4 
[2.0-53.8] and 2.4 [1.0-5.9], respectively (Table 4), while no association was observed for women. 
The associations were stronger when the relatives' disease had been diagnosed before the age of 45 
years. The same pattern was observed for MM, although it was not significant, but not for LPS. Most 
frequently, the relatives' hematopoietic cancer had occurred at least 10 years before the diagnosis 
(cases) or interview (controls). 
The associations between LPS subtypes, CLL and HCL, and a family history of hematopoietic cancer 
were close to those observed for the whole LPS group (Table 5). Similar associations were also 
observed for the FL and DLCL NHL subtypes. 
More detailed information on the relatives' cancers showed that HL and NHL were only associated 
with a family history of lymphoma, while LPS was related to a history of lymphoma and leukemia 
(Table 6). Some positive associations with specific solid cancer sites, particularly kidney cancer for 
NHL (OR = 4.1 [1.0-16.8]) and HL (OR = 18.2 [1.3-251]), breast cancer for LPS (OR = 1.9 [1.1-3.7]), 
colon cancer for NHL (OR = 2.7 [1.6-4.6]) and melanoma for MM (OR = 13.6 [1.1-162]) were also 
observed (Table 6). 
In order to investigate for potential familial anticipation, the 30 cases (12 LPS (11 CLL, 1 HCL), 9 
NHL, 6 HL and 3 MM) who reported parents’ hematopoietic cancer were considered separately. 
The 6 cases of CLL with a parent who had had leukemia (not otherwise specified) were diagnosed at 
ages ranging from 43 to 64 years (average: 55 years), while their parents were 56 to 83 years old at the 
time of diagnosis (average: 70 years). Only 3 NHL cases had parent who had had NHL. The cases 
were also younger than their affected parent (56 years [52 to 59] vs 65 years [59 to 71]). Lastly, 4 LH 
cases had parents who had had LH. The cases did not seem to be younger at the time of diagnosis than 
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their affected parent (36 years [21 to 51] vs 26 years [20 to 32]). Within those pairs, the parents were 
diagnosed at an early age in 4 out of 6 pairs of CLL (not otherwise specified for the parent), 3 out of 3 
pairs of NHL and 2 out of 4 pairs of HL. The numbers were too small for other combinations of cases 
and parents diagnoses to be investigated. 
Seven cases (4 NHL, 1 HL, 1 LPS, 1 MM) reported that their spouses (5 husbands and 2 wives) had 
been diagnosed with a hematopoietic cancer, but no control did. Only 3 couples had concordant 
diagnoses of NHL (as a whole). Interestingly, for 5 of the 7 affected spouses, including the 3 NHL-
NHL couples, the disease was diagnosed 5 years or less before the case diagnosis. The small numbers 
preclude accurate OR estimation. The spouses of 58 cases and 53 controls (OR = 1.0 [0.7-1.5]) had 
had cancer (any type). (Tables 3, 4, 5, 6 here). 
Additional adjustments and sensitivity analyses 
The results were unchanged after adjustment for the number and age of the relatives, and for 
educational level and socioeconomic category. Conditional logistic regression models using the initial 
matching instead of age, gender and centre strata yielded similar results. The results did not change 
when each centre was excluded in turn or when the reason for admission of each group of controls was 
excluded in turn. 
DISCUSSION 
The present study showed that LN, and particularly LPS, was associated with a history of 
hematopoietic cancer in first-degree relatives. For HL and NHL, the associations seemed to be 
restricted to men, particularly when the hematopoietic cancer had occurred in relatives before the age 
of 45 years. 
The inclusion of the cases was independent of their family history. The cases were recruited in main 
hospitals that were unlikely to attract specific patient categories. All eligible cases hospitalized in the 
department on the interviewers’ working days were systematically contacted and the high participation 
rate (94.5%) made high self-selection on family history unlikely. In addition, the cases were included 
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just after diagnosis to prevent survival bias that might have overrepresented cases with a family 
history in the event that the history was related, directly or indirectly, to a factor for a superior 
prognosis. 
The cases and controls were hospitalized in the same center and resided in its catchment area. The 
controls were mainly recruited in orthopedic and rheumatologic departments, and were not to have 
been admitted for a disease directly related to smoking, alcohol intake or occupation, although they 
could have had those diseases in the past. Those precautions were taken to avoid artificial over- or 
under-representation of certain risk factors or socioeconomic categories that might be related to a 
family history of cancer or history reporting by the controls. In addition, the participation rate was 
quite high (88.3%), making self-selection on family history more improbable. 
Over- or under-reporting was more possible in that the information was obtained by interview and not 
documented by medical reports. The cases were more conscious of their disease and perhaps more 
prone to having obtained information on their family history and relatives' cancer. However, the study 
focused on first-degree relatives (parents, siblings, children), whose medical history is less likely to be 
different for cases and controls. Moreover, the questionnaires were standardized and the cases and 
controls were interviewed under the same conditions in order to reduce the opportunity for differential 
misclassifications. Non-differential misclassifications were also reduced by those measures, but could 
not be completely prevented since it was not possible to access objective information (anonymous 
data). The misclassifications are probably stronger for specific types of cancer than for broad 
categories. In addition, some LH or NHL diagnoses in relatives may have been confused: cases may 
have been influenced by their own diagnosis when they reported a history of lymphoma in their 
relatives 
Several studies have quantified misclassifications by comparing the reported family history of cancer 
with the relatives' medical files. Strong concordances were observed for cancer in first-degree relatives 
26
-
27
-
28
-
29
-
30
-
31
. Differences were observed for some cancer sites 26-28-32-30-31-32. The greatest differences 
were reported for hepatic, uterine and cervical disease sites 26-27-33-31. 
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The reporting of cancer in offspring and, to a lesser extent, siblings was hampered by censoring by 
age. This probably reduced the power of the study, particularly for HL. The power was also weak for 
women and for multiple myeloma, due to small numbers. 
Socioeconomic category is a strong potential confounder since it is usually related to the risk of 
smoking-related cancer in the family and to the quality of the report, assumed to be more accurate in 
more educated subjects. However, analyses were adjusted for socioeconomic category and the results 
were very similar. 
The Epilymph study 34 also showed a significant and positive association between lymphoid neoplasm 
taken as a whole and a history of hematopoietic cancer in first degree relatives. Several studies have 
shown specific associations between a familial history of hematopoietic cancer and LPS 35-34-36-37-38, 
NHL34-39-33-40, and HL 41. However, in the present study, the latter two relationships were not 
significant when both genders were considered together. The OR were higher for men, which has also 
been observed in two other studies 25-33. The associations were not only stronger in males, but they 
were also mostly due to hematopoietic cancers in male relatives. These results suggest a sex-linked 
genetic susceptibility to hematopoietic cancers. Stronger associations between hematopoietic cancer in 
male relatives were also reported for HL and NHL in a study in the US 22 and for CLL in the Swedish 
Family-Cancer Database 37. 
Two studies on MM showed associations with parental history of MM 21-42. The present study did not 
evidence any such association. HL and NHL were mainly associated with lymphomas in relatives, 
which supports the results of previous studies 21-34-41-37-25-23-39-33. 
Anticipation of CLL diagnosis in CLL case families, which implies that CLL presents earlier than in 
the preceding generation, has been suggested in a few studies 37-43-44-45 but not that of the Swedish 
Family-Cancer Database 37-46. The finding in the present study, based on 6 CLL-CLL parent-case pairs 
is compatible with anticipation. The cases were more conscious of their disease and perhaps more 
prone to having obtained information on their family history and relatives' cancer, which may induce a 
recall bias. However, the study focused on first-degree relatives (parents, siblings, children), whose 
medical history is less likely to be differentially reported for cases and controls. 
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Daugherty et al (2005)46, using data from the Swedish Family-Cancer Database and the Danish 
registry, showed that the secular trends in incidence and diagnosis of NHL could give rise to apparent 
anticipation. They did not evidence any anticipation of HL, CLL and MM cases. . Secular trends and 
censoring of the youngest parents may result in false anticipation. Moreover, in CLL, anticipation was 
assumed to be due to an increase in genomic instability over succeeding generations, but studies of 
nucleotides repeats did not support that hypothesis ( Auer et al, 2001)47. 
The study showed associations between both NHL and HL and a family history of kidney and 
digestive tract cancers, between LPS and a family history of breast cancer, and between MM and a 
family history of melanoma. The analysis was not hypothesis-driven. The numbers were small and 
resulted in wide confidence intervals. Multiple tests increased the risk that an association may have 
occurred by chance. Therefore, the results are to be considered exploratory. A few studies have 
reported associations between LN and solid tumors, but no clear consistency has emerged. 
Associations between NHL and kidney cancer33 or colorectal cancers41-38, and between breast cancer 
and LPS38 have been reported and are in line with the results of the present study. In contrast, to the 
authors' knowledge, the association between MM and a family history of melanoma has never been 
reported. 
The study also showed a slight trend toward cases reporting hematopoietic cancer in the spouse more 
frequently than controls. Spouses may be assumed to be aware of each other’s health; recall bias is 
thus rather unlikely. However, the numbers are small and the trend may be a chance finding. Out of 
the three studies that investigated cancer among spouses 48-49-50, a Japanese study 50 showed an 
increase in all malignant neoplasm in spouses and an American study 48 showed an increase in NHL. 
As they stand, the results of the present study do not strongly support an increase in hematopoietic 
cancer in spouses similar to that in first degree relatives. Nonetheless, it is still possible that a part of 
familial aggregation results from an environmental exposure – possibly to an infectious agent – shared 
by the family. However, the predominance of the association with a history of hematopoietic cancer in 
men, particularly for HL, suggests a sex-linked genetic predisposition. 
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CONCLUSION 
In conclusion, the results mainly support the involvement of genetic factors in the aetiology of NHL, 
and suggest that at least some of those factors could be sex-linked. However, the slight 
overrepresentation of affected spouses among the cases may also support the responsibility of 
environmental factors. 
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Table 1: Distribution of cases and controls by stratification variable: age, gender and centre. 
  LPS  NHL  HL  MM 
  Cases Controls Controls  Cases Controls Controls  Cases Controls Controls  Cases Controls Controls 
  n = 168 n = 464 per case  n = 397 n = 701 per case  n = 149 n = 417 per case  n = 108 n = 478 per case 
Centre  ***  *  ns  ns 
Brest  22 111 5.0  86 140 1.6  22 73 3.3  21 107 5.1 
Caen  64 90 1.4  24 84 3.5  16 51 3.2  10 54 5.4 
Nantes  26 71 2.7  76 117 1.5  40 106 2.7  12 57 4.8 
Lille  29 60 2.1  30 65 2.2  5.5 8 1.6  13 47 3.6 
Toulouse  9 54 6.0  77 137 1.8  34 90 2.6  21 91 4.3 
Bordeaux  16 75 4.7  104 158 1.5  32 89 2.8  26 117 4.5 
Paris  2 3 1.5  - - -  - - -  5 5 1.0 
                 
Age (year) ns  ns  ***  ns 
< 25  - - -  10 28 2.8  35 38 1.1  - - - 
[25-29]  - - -  9 22 2.4  20 32 1.6  - - - 
[30-34]  - - -  16 28 1.8  16 26 1.7  1 2 2.0 
[35-39]  5 19 3.8  22 41 1.9  16 35 2.2  2 11 5.5 
[40-44]  8 17 2.1  31 56 1.8  18 38 2.1  3 13 4.3 
[45-49]  14 46 3.3  40 66 1.7  14 53 3.8  9 42 4.7 
[50-54]  22 63 2.9  69 121 1.8  10 74 7.4  19 113 5.9 
[55-59]  35 85 2.5  66 91 1.4  4 38 9.5  15 73 4.9 
[60-64]  28 94 3.4  46 102 2.2  5 33 6.6  24 93 3.9 
[65-69]  33 74 2.2  45 75 1.7  10 42 4.2  22 72 3.3 
≥ 70  23 66 2.9  45 71 1.6  1 6 6.0  13 59 4.5 
                 
Mean age (SD)   60(9) 59(9)   54(12) 53(12)   34(14) 46(14)   59(9) 59(9)  
                 
Gender  ns  ns  ns  ** 
Female  64 159 2.5  155 265 1.7  62 152 2.5  52 165 3.2 
Male  104 305 2.9  244 436 1.8  87 265 3.0  56 313 5.6 
LPS: lymphoproliferative syndrome, NHL: non-Hodgkin’s lymphoma, HL: Hodgkin’s lymphoma, MM: multiple myeloma, ns: not significant, SD: standard deviation 
* p<0.05, **p<0.01, ***p<0.0001,  
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Table 2: Comparability of cases and controls by familial structure and socioeconomics characteristic  
 LPS  NHL  HL  MM 
 Ca Co OR 95% CI  Ca Co OR 95% CI  Ca Co OR 95% CI  Ca Co OR 95% CI 
Education ns  ns  *  ns 
< high school 126 348 1.0 ref  270 484 1.0 ref  65 260 1.0 ref  76 349 1.0 ref 
≥ high school 42 116 1.3 [0.8-1.9]  129 217 1.1 [0.8-1.4]  84 157 1.5 [1.1-2.3]  32 129 1.2 [0.8 -2.0] 
                    
Socioeconomic category ns  ns  *   ns 
Unemployed 1 8 0.5 [0.1-3.7]  11 26 0.8 [0.3-1.6]  21 26 0.8 [0.4-1.8]  3 14 0.9 [0.2 -.3.2] 
White collar 85 207 1.0 ref  188 311 1.0 ref  82 179 1.0 ref  50 208 1.0 ref 
Blue collar 82 249 0.8 [0.5-1.1]  200 364 0.9 [0.7-1.2]  46 212 0.5 [0.3-0.8]  55 256 0.9 [0.2 -3.2] 
   
 
    
 
    
 
    
 
 
Number of relatives ns  ns  ns  ns 
2 to 3 9 25 1.0 [0.4-2.3]  48 74 1.7 [1.1-2.8]  40 68 1.5 [0.7-3.3]  10 34 1.4 [0.6 -3.2] 
4 to 5 46 116 1.2 [0.8-1.5]  122 186 1.4 [1.0-2.0]  41 109 1.5 [0.8-3.0]  28 121 1.2 [0.7 -2.1] 
6 to 7 43 135 1.0 [0.6-1.5]  114 199 1.2 [0.9-1.7]  48 116 2.2 [1.2-4.1]  34 34 1.2 [0.7 -2.2] 
8 and more 70 188 1.0 ref  113 242 1.0 ref  20 124 1.0 ref  36 180 1.0 ref 
   
 
    
 
    
 
    
 
 
Relatives’ mean age (SD) 55(8) 54(8) ns  52(10) 51(10) ns  43(11) 47(10) ns  56(9) 54(9) ns 
LPS: lymphoproliferative syndrome, NHL: non-Hodgkin’s lymphoma, HL: Hodgkin’s lymphoma, MM: multiple myeloma, ns: not significant, SD: standard deviation 
OR estimated by unconditional logistic regression adjusted for gender, age and centre. 
*p≤0.05 
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Table 3: Relationships between lymphoid neoplasm (LN) and family history of any cancer in first-degree relatives 
 All LN  LPS  NHL  HL  MM 
 Ca Co  Ca Co  Ca Co  Ca Co  Ca Co 
 n = 822 n = 752 OR 95% CI  n = 168 n = 464 OR 95% CI  n = 397 n = 701 OR 95% CI  n = 149 n = 417 OR 95% CI  n = 108 n = 478 OR 95% CI 
Any cancer 
At any age 368 317 1.1 [0.9-1.3]  97 227 1.3 [0.9-1.9]  176 303 1.0 [0.8-1.3]  45 147 1.3 [0.8-2.0]  50 228 1.0 [0.6-1.5] 
< 45 years 61 49 0.7 [0.5-1.2] 3 11 2.1 [0.4-11.2] 31 44 0.6 [0.4-1.1] 26 38 0.8 [0.4-1.4] 1 9 3.3 [0.3-44.7] 
45-60 years 199 181 1.0 [0.7-1.4] 47 139 2.0 [1.1-3.6] 112 179 0.9 [0.6-1.3] 18 124 0.9 [0.4-2.1] 22 157 0.5 [0.3-1.1] 
≥ 60 years  156 133 1.1 [0.8-1.6] 48 120 1.1 [0.7-1.9] 66 126 1.0 [0.6-1.5] 7 34 1.0 [0.3-3.0] 35 109 1.6 [0.9-2.9] 
Number of relatives with cancer 
1 257 233 1.0 [0.8-1.3]  60 168 1.2 [0.7-1.7]  126 224 1.0 [0.7-1.3]  35 120 1.2 [0.7-2.0]  36 164 1.0 [0.6-1.5] 
≥ 2 111 84 1.2 [0.9-1.7]  37 59 1.9 [1.1-3.2]  50 79 1.2 [0.8-1.7]  10 27 1.6 [0.7-3.7]  14 64 1.0 [0.5-1.9] 
Gender of relatives with cancer 
Male 244 217 1.0 [0.8-1.3]  75 155 1.6 [1.0-2.5]  105 207 0.8 [0.6-1.1]  27 97 1.1 [0.6-2.0]  37 157 1.1 [0.7-1.9] 
Female 205 155 1.3 [1.0-1.6]  53 114 1.3 [0.8-2.0]  104 148 1.3 [0.9-1.8]  25 70 1.5 [0.8-2.7]  23 114 0.9 [0.5-1.5] 
Age of relatives at cancer onset 
< 45 years  51 35 1.5 [0.9-2.3]  9 24 1.6 [0.7-3.8]  26 35 1.4 [0.8-2.4]  11 17 2.1 [0.9-5.1]  5 20 1.3 [0.5-3.8] 
≥ 45 years  209 177 1.1 [0.9-1.4]  54 129 1.3 [0.8-1.9]  104 168 1.1 [0.8-1.4]  25 77 1.4 [0.8-2.5]  26 136 0.8 [0.5-1.3] 
Hematopoietic cancer  
At any age 48 26 1.7 [1.0-2.8]  16 15 3.2 [1.4-6.8]  19 25 1.3 [0.7-2.5]  8 10 2.4 [0.8-7.1]  5 19 1.2 [0.4-3.3] 
< 45 years 10 5 0.5 [0.2-1.5]  1 1 0.7 [0.01-15.8]  4 4 0.4 [0.1-1.9]  5 4 0.5 [0.12-2.0]  0 1 - - 
45-60 years 199 181 2.1 [1.0-4.3]  47 139 3.4 [1.1-10.8]  112 179 1.9 [0.8-4.5]  18 124 3.5 [0.6-22.2]  22 157 1.9 [0.5-7.9] 
≥ 60 years  12 10 1.0 [0.4-2.5]  7 8 2.8 [0.9-8.6]  2 10 0.3 [0.1-1.6]  1 2 2.6 [0.2-38.4]  2 9 0.8 [0.2-3.9] 
Number of relatives with hematopoietic cancer 
1 46 23 1.8 [1.1-3.1]  15 13 3.7 [1.6-8.3]  19 22 1.5 [0.8-2.8]  8 9 2.9 [1.0-8.5]  4 17 1.1 [0.3-3.4] 
≥ 2 2 3 0.6 [0.1-3.6]  1 2 0.8 [0.1-9.9]  0 3 - -  0 1 - -  1 2 2.0 [0.2-24.2] 
Gender of relatives with cancer 
Male 31 18 1.5 [0.8-2.8]  10 9 3.1 [1.2-8.5]  12 17 1.2 [0.6-2.6]  4 6 2.1 [0.5-8.6]  5 12 2.2 [0.7-7.1] 
Female 19 9 1.8 [0.8-4.1]  7 6 2.7 [0.8-8.6]  7 9 1.3 [0.4-3.3]  4 5 2.3 [0.5-10.6]  1 7 0.6 [0.1-5.1] 
Age of relatives at cancer onset 
< 45 years  16 7 2.2 [0.9-5.3]  2 6 1.0 [0.2-5.4]  8 7 2.2 [0.8-6.3]  5 1 15.6 [1.6-154]  1 5 0.9 [0.1-8.7] 
≥ 45 years  19 11 1.5 [0.7-3.3]  7 8 2.4 [0.8-7.4]  9 11 1.4 [0.5-3.4]  1 3 1.0 [0.1-11.7]  2 10 0.8 [0.5-3.9] 
LPS: lymphoproliferative syndrome, NHL: non-Hodgkin’s lymphoma, HL: Hodgkin’s lymphoma, MM: multiple myeloma,  
OR estimated by unconditional logistic regression adjusted for gender, age, centre, socioeconomic category 
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Table 4: Associations between lymphoid neoplasms (LN) and family history of hematopoietic cancer in first-degree relatives by gender 
 
 All LN  LPS  NHL  HL  MM 
 
 OR 95% CI  OR 95% CI  OR 95% CI  OR 95% CI  OR 95% CI 
Both Any hematopoietic cancer in relatives 1.7 [1.0-2.8]  3.2 [1.4-6.8]  1.3 [0.7-2.5]  2.4 [0.8-7.1]  1.2 [0.4-3.3] 
 
Characteristics of relatives  
 
  
 
  
 
  
 
  
 
 
 
Men 1.5 [0.8-2.8]  3.1 [1.2-8.5]  1.2 [0.6-2.6]  2.1 [0.5-8.6]  2.2 [0.7-7.1] 
 
Women 1.8 [0.8-4.1]  2.7 [0.8-8.6]  1.3 [0.4-3.3]  2.3 [0.5-10.6]  0.6 [0.1-10.0] 
 
< 45 years at onset 2.2 [0.9-5.3]  1.0 [0.2-5.4]  2.2 [0.8-6.3]  15.6 [1.6-154]  0.9 [0.1-8.7] 
 
≥ 45 years at onset 1.5 [0.7-3.3]  2.4 [0.8-7.4]  1.4 [0.5-3.4]  1.0 [0.1-11.7]  0.8 [0.5-3.9] 
 
 
 
  
 
  
 
  
 
  
 
 
Men Any hematopoietic cancer in relatives 3.0 [1.4-6.5]  3.5 [1.1-10.5]  2.4 [1.0-5.9]  10.4 [2.0-53.8]  1.7 [0.3-9.0] 
 
Characteristics of relatives 
 
  
 
  
 
  
 
  
 
 
 
Men 3.2 [1.0-10.2]  4.8 [0.9-25.8]  2.1 [0.6-7.8]  26.2 [1.6-438]  5.9 [0.9-40.6] 
 
Women 1.8 [0.6-5.4]  1.7 [0.3-8.2]  1.6 [0.4-5.8]  8.3 [1.0-70.5]  0 ca/5 co 
 
< 45 years at onset 3.8 [1.1-14.0]  0 ca /2 co  5.2 [1.3-21.2]  3 ca/0 co  2.2 [0.2-23.7] 
 
≥ 45 years at onset 1.1 [0.3-37.0]  1.6 [0.3-10.0]  1.2 [0.3-4.6]  0 ca/2 co  0 ca/5 co  
 
 
 
  
 
  
 
  
 
  
 
 
Women Any hematopoietic cancer in relatives 1.1 [0.6-2.3]  2.8 [0.9-8.4]  0.7 [0.2-1.9]  0.9 [0.2-4.3]  0.9 [0.2-3.7] 
 
Characteristics of relatives 
 
  
 
  
 
  
 
  
 
 
 
Men 1.2 [0.5-2.7]  2.2 [0.5-9.1]  0.6 [0.2-2.3]  1.1 [0.1-7.8]  0 ca/2 co 
 
Women 1.7 [0.5-6.2]  3.7 [0.7-31]  0.5 [0.0-4.6]  0.6 [0.0-9.3]  1.0 [0.2-6.1] 
 
< 45 years at onset 0.8 [0.2-3.6]  1.2 [0.2-8.0]  0 ca/4 co  5.6 [0.3-97.7]  0 ca/2 co 
 
≥ 45 years at onset 2.2 [0.7-5.5]  2.8 [0.6-12]  1.4 [0.4-5.1]  2.8 [0.1-74.2]  1.0 [0.2-6.1] 
LPS: lymphoproliferative syndrome, NHL: non-Hodgkin’s lymphoma, HL: Hodgkin’s lymphoma, MM: multiple myeloma,  
OR estimated by unconditional logistic regression adjusted for gender, age, centre, socioeconomic category 
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Table 5 : Associations between LPS and NHL subtypes and family history of hematopoietic cancer in first degree relatives 
by gender 
 
 LPS  NHL 
  
  CLL (n=132)   HCL (n=36)   FL (n=101)   DLCL (n=172) 
  
  OR 95% CI   OR 95% CI   OR 95% CI   OR 95% CI 
Both Any hematopoietic cancer in relatives 3.3 [1.4-7.4]  3.4 [0.8-13.5]  1.0 [0.3-2.9]  1.7 [0.8-3.7] 
 
Characteristics of relatives  
 
  
 
  
 
  
 
 
 
Men 3.1 [1.1-9.1]  5.9 [1.0-35.9]  1.4 [0.4-4.4]  1.1 [0.4-3.2] 
 
Women 2.9 [0.9-9.9]  2.1 [0.2-20.5]  0 ca /9 co  2.3 [0.7-7.3] 
 
< 45 years at onset 1.1 [0.2-5.8]  - -  2.0 [0.4-10.2]  2.9 [0.8-10.8] 
 
≥ 45 years at onset 2.3 [0.7-8.2]  3.9 [0.8-22.0]  1.1 [0.2-5.4]  1.4 [0.4-4.5] 
 
 
 
  
 
  
 
  
 
 
Men Any hematopoietic cancer in relatives 3.5 [1.0-12.8]  2.9 [0.4-19.3]  2.0 [0.4-8.6]  2.5 [0.8-7.7] 
 
Characteristics of relatives 
 
  
 
  
 
  
 
 
 
Men 3.2 [0.5-21.9]  20.1 [1.7-240.8]  5.1 [0.8-33.0]  1.2 [0.1-7.9] 
 
Women 2.2 [0.4-12.1]  0 ca /4 co  0 ca /5 co  2.5 [0.6-10.5] 
 
< 45 years at onset 0 ca /2 co  0 ca /2 co  5.7 [0.7-44.7]  5.7 [1.1-30.2] 
 
≥ 45 years at onset 1.4 [0.1-14.8]  1.5 [0.1-18.0]  1.1 [0.1-10.6]  0.8 [0.1-6.7] 
 
 
 
  
 
  
 
  
 
 
Women Any hematopoietic cancer in relatives 2.5 [0.8-8.2]  11.9 [0.2-613.5]  0.4 [0.0-3.6]  1.1 [0.3-4.1] 
 
Characteristics of relatives 
 
  
 
  
 
  
 
 
 
Men 2.2 [0.5-9.0]  0 ca /6 co  0.3 [0.0-3.6]  1.0 [0.2-5.1] 
 
Women 2.6 [0.3-23.0]  1 ca /2 co  0.5 [0.0-4.6]  0.8 [0.1-8.6] 
 
< 45 years at onset 1.4 [0.2-9.6]  0 ca /4 co  0 ca/4 co  0 ca/4 co 
  
≥ 45 years at onset 2.2 [0.4-11.7]   28.6 [0.6-∞]   0.8 [0.1-11.2]   2.0 [0.4-9.3] 
CLL: chronic lymphoid leukemia, HCL : hairy cell leukemia, FL: follicular lymphoma, DLCL: diffuse large B cell lymphoma, OR estimated by 
unconditional logistic regression adjusted for gender, age, centre, socioeconomic category 
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Table 6: Associations between lymphoid neoplasm (LN) and family history of cancer by site of cancer in first degree relative  
 All LN   LPS  NHL  HL  MM 
 Ca Co  Ca Co  Ca Co  Ca Co  Ca Co 
 n = 822 n = 752 OR 95% CI  n = 168 n = 464 OR 95% CI  n = 397 n = 701 OR 95% CI  n = 149 n = 417 OR 95% CI  n = 108 n = 478 OR 95% CI 
Solid cancer 314 267 1.1 [0.9-1.3]  86 200 1.3 [0.9-1.9]  148 258 1.0 [0.8-1.3]  35 121 1.3 [0.8-2.0]  45 195 1.1 [0.7-1.7] 
Head & neck 30 26 1.0 [0.6-1.7]  16 21 2.0 [1.0-4.1]  9 25 0.6 [0.3-1.3]  2 11 0.7 [0.2-3.7]  3 16 0.9 [0.2-3.2] 
Lung 54 44 1.2 [0.8-1.8]  10 37 0.7 [0.3-1.6]  29 43 1.3 [0.8-2.1]  6 19 1.6 [0.6-4.4]  9 38 1.2 [0.5-2.6] 
Digestive 128 94 1.3 [0.9-1.7]  32 76 1.1 [0.7-1.7]  62 90 1.3 [0.9-1.9]  15 35 2.1 [1.0-4.2]  19 71 1.2 [0.7-2.2] 
Colon 50 27 1.0 [0.5-2.0]  1 7 0.4 [0.0-3.6]  35 25 2.7 [1.6-4.6]  6 12 1.8 [0.6-5.4]  0 19 - - 
Breast 77 59 1.2 [0.8-1.7]  25 41 1.9 [1.1-3.7]  37 59 1.1 [0.7-1.7]  5 29 0.7 [0.2-1.8]  10 44 0.9 [0.4-2.0] 
Skin 13 9 1.3 [0.5-3.0]  3 4 1.9 [0.4-9.3]  4 8 0.9 [0.3-3.2]  4 6 1.6 [0.4-6.6]  2 4 2.7 [0.5-15.6] 
Melanoma 7 4 1.5 [0.4-5.3]  2 1 4.1 [0.3-51.8]  2 3 1.2 [0.2-7.4]  1 3 0.8 [0.1-8.9]  2 1 13.6 [1.1-162] 
Bone 2 6 0.3 [0.1-1.4]  1 6 0.5 [0.1-4.5]  0 6 - -  0 4 - -  1 4 1.0 [0.1-12.0] 
Genitourinary 75 67 1.0 [0.7-1.4]  22 47 1.3 [0.7-2.2]  33 65 0.8 [0.5-1.3]  7 32 0.8 [0.3-1.9]  13 47 1.2 [0.6-2.4] 
Kidney 11 3 2.9 [0.8-10.6]  0 2 - -  7 3 4.1 [1.0-16.8]  2 1 18.2 [1.3-251]  2 2 5.6 [0.7-46.2] 
CNS 14 10 1.3 [0.6-2.9]  3 5 1.4 [0.3-6.4]  9 9 1.8 [0.7-4.6]  1 6 0.5 [0.1-4.5]  1 5 1.5 [0.2-13.3] 
Thyroid 5  1.1 [0.3-4.2]  1 4 0.4 [0.0-4.3]  3 4 1.4 [0.3-6.7]  0 1 - -  1 2 1.6 [0.1-19.5] 
Hematopoietic                        
cancer 48 26 1.7 [1.0-2.8]  16 15 3.2 [1.4-6.8]  19 25 1.3 [0.7-2.5]  8 10 2.4 [0.8-7.1]  5 19 1.2 [0.4-3.4] 
Lymphoma 19 6 3.0 [1.2-7.7]  3 2 9.9 [1.4-71.5]  7 6 1.8 [0.6-5.4]  8 2 14.0 [2.6-74.3]  1 5 0.5 [0.1-4.6] 
HL 9 2 4.6 [1.0-21.9]  1 1 9.1 [0.4-214]  2 2 1.6 [0.2-11.9]  5 1 18.0 [1.8-184]  1 1 4.0 [0.2-73.7] 
NHL 11 4 2.4 [0.8-7.7]  2 1 10.2 [0.8-128]  5 4 1.8 [0.5-6.9]  3 1 9.1 [0.8-102]  1 4 0.6 [0.1-5.5] 
Leukemia 29 20 1.3 [0.7-2.3]  13 12 2.8 [1.2-6.5]  12 19 1.1 [0.5-2.4]  0 9 - -  4 13 1.9 [0.6-6.1] 
Myeloma 1 1 0.9 [0.1-15.1]  1 1 1.5 [0.1-2.7]  0 1 - -  - - - -  0 1 - - 
LPS: lymphoproliferative syndrome, NHL: non-Hodgkin’s lymphoma, HL: Hodgkin’s lymphoma, MM: multiple myeloma,  
OR estimated by unconditional logistic regression adjusted for gender, age, centre and socioeconomic category 
